Key facts
- It has raised $31.3M; the latest was Later Stage VC ($2.8M) in Sep 2025.
- Notable investors include Partners Investment, CJ Investment, BNH Investment, CKD Venture Capital, Company K Partners — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Medinno
- ·The full record, as it builds
Funding rounds
No funding rounds for Medinno are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Medinno
Developer of cell therapeutics designed to cure degenerative brain diseases such as stroke and Alzheimer's disease. The company's therapy leverages technology to cure a variety of diseases like hypoxic-ischemic encephalopathy, neonatal refractory brain diseases and severe intraventricular hemorrhages, enabling physicians to effectively counter degenerative diseases in premature infants.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2018
- Employees
- 27
- Website
- medinno.kr/
- Ownership
- Privately Held (backing)
Medinno doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Medinno shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Medinno in its N-PORT filings yet. We sweep new filings monthly.